Skip to content
Swedish Orphan Biovitrum (Sobi)
-
Sobi strikes US$580M lacutamab deal with Innate Pharma for CTCL
The study is designed to provide confirmatory evidence for lacutamab in two CTCL subtypes, Sézary syndrome and mycosis fungoides, potentially supporting full regulatory approval.